Genetics

uniQure N.V. presented new clinical data from the ongoing Phase I-II trial of AMT-060.

uniQure N.V. (NASDAQ:QURE) presented new clinical data from the ongoing Phase I-II trial of AMT-060.
As quoted in the press release:

Clinical data [demonstrates] that the presence of pre-existing anti-AAV5 neutralizing antibodies (NABs) does not predict the potential efficacy of AAV5-mediated gene transfer in patients with hemophilia B. Clinically meaningful factor IX (FIX) activity levels from the ongoing Phase I-II trial of AMT-060 were observed at NAB titers up to 1:341, determined as corresponding up to the 90th percentile of a healthy control population. NABs were quantified in the blood sera of these patients using a highly sensitive assay. These clinical data were presented today in a poster presentation at the 26th Biennial Congress of the International Society on Thrombosis and Hemostasis (ISTH), taking place this week in Berlin, Germany.

The presence of pre-existing NABs to adeno-associated virus (AAV) vectors has long posed a critical challenge for the clinical application of gene therapies, as patients who currently screen positive for NABs are generally excluded from treatment. Researchers from uniQure recently presented data in non-human primates suggesting that AAV5 could successfully mediate gene transfer in the presence of NABs at levels as high as 1:1031.

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX19385.88-174.28
TSXV630.50-6.99
DOW30822.42-139.40
S&P 5003873.33-28.02
NASD11448.40-103.95
ASX6842.90+14.30

COMMODITIES

Commodities
Gold1673.96+11.46
Silver19.56+0.59
Copper3.54+0.05
Palladium2126.00+8.00
Platinum910.00+9.50
Oil85.25+0.15
Heating Oil3.18-0.02
Natural Gas7.81-0.51

DOWNLOAD FREE REPORTS

×